Sarah Cannon Research Institute Adds Physician Researcher

May 11, 2005

Applied Clinical Trials

Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator.

NASHVILLE, Tenn., May 11, 2005 -- Sarah Cannon Research Institute (SCRI) has named Anthony A. Meluch, M.D. as a primary investigator. A clinical researcher with The Sarah Cannon Cancer Center since 1993, Meluch is also a member of Tennessee Oncology, P.L.L.C.

Dr. Meluch joins SCRI's primary investigator team, directed by F. Anthony Greco, M.D., which also includes John D. Hainsworth, M.D., Howard A. Burris III, M.D., Denise A. Yardley, M.D., David Spigel, M.D. and Suzanne F. Jones, PharmD.

"Dr. Meluch is a thought leader who brings excellent qualifications and experience to our team," said Dr. Greco. "His research interests and passion for advancing patient care will enable us to expand our menu of clinical trials."

Meluch received his undergraduate training at St. Louis University in Missouri, and his medical doctorate from The Ohio State University College of Medicine. He completed an internal medicine residency program and then a fellowship in both hematology and oncology at the University of Alabama in Birmingham; he is board certified in all three subspecialties. His research interests and publications are in malignancies of the upper aerodigestive system, esophagus, head, neck and genitourinary tract.

"Dr. Meluch's vast knowledge and experience as a practicing physician and researcher made him the perfect candidate for this role," said Mark Cianciolo, CEO of Sarah Cannon Research Institute. "His appointment is in line with our goals to expand our team of physician researchers to enhance our ability to develop more clinical trials for more patients."

"I am honored and excited by the opportunity to further my research interests and expand the scope of SCRI's investigations to improve outcomes for people fighting cancer," said Dr. Meluch.

Sarah Cannon Research Institute, a new company created by HCA's MidAmerica Division and Tennessee Oncology, is dedicated to creating and advancing solutions for a healthier tomorrow through clinical research. The institute is the largest community-based research program in the United States, currently conducting clinical trials through a network of more than 600 oncologists in 25 states.

Related Content:

News